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Résumé en
anglais
The Centralized Chemotherapy Reconstitution Unit (CCRU) of Paul Brousse Hospital
Pharmacy Department assessed the reliability of its Cytotoxics Compounded Sterile
Products (CCSP) preparation method in order to improve its CCSP quality assurance
system. Five cytotoxic drugs — gemcitabine, 5-fluorouracil, docetaxel, paclitaxel,
and oxaliplatin — were assayed by high performance liquid chromatography (HPLC)
to determine CCSP concentration. During the observation period, 23,892 CCSP were
prepared. Overall, 12,964 preparations contained one of the five analyzed drugs;
7382 (56.9%) out of 12,964 CCSP were analyzed by HPLC; 646 (8.8%) out of 7382
concentrations were outside ± 20% of the prescribed dose; 544 (84.2%) out of 646
were post-administration results and could not be verified. Out of 102 (15.8%) pre-
administration results that were re-tested after re-shaking, 94 (92.2%) were found to
be acceptable upon re-testing, and 8 (7.8%) were confirmed to be unacceptable and
needed to be re-compounded. The 8.8% of tested CCSP were outside ± 20% of the
prescribed dose, but extrapolating the results on re-tested CCSP, we can say that
our CCSP preparation is reliable with an estimation of only 0.7% of 7382 CCSP
analyzed, confirmed as being ± 20% outside the prescribed dose. Nevertheless, this
± 20% magnitude of error should be reduced. Based on pre-administration results,
the primary cause of concentration errors appeared to be insufficient mixing of the
finished product. Most CCSP dosages occurred after it had been administered, the
organization should, therefore, be improved to include testing all CCSP prior to
administration. Pharmaceutical companies should endeavor to manufacture
compounded injectible drugs in a ‘ready to use’ form and provide vehicles in
accurate volumes in order to improve compounding precision.
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